RaQualia Pharma Inc.
JPX: 4579.T0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Tokyo Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Masaki Sudo
- Employees
- 64
- Headquarters
- Nagoya, Japan
- IPO year
- 2011
- Market cap
- ¥19.4B
- Website
- https://www.raqualia.co.jp
Loading 4579…
Loading profile data…Frequently asked questions about 4579
What does RaQualia Pharma Inc. (4579.T) do?
RaQualia Pharma Inc. engages in the research and development of pharmaceutical compounds worldwide. Its human products portfolio includes tegoprazan for gastroesophageal reflux disease, which is in phase 1 clinical trial in the United States; and grapiprant for pain management, which is in phase II clinical trial in the United States and phase I...
Where does 4579.T trade?
RaQualia Pharma Inc. (4579.T) trades on the Tokyo Stock Exchange.
What sector is 4579.T in?
RaQualia Pharma Inc. (4579.T) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of RaQualia Pharma Inc.?
Masaki Sudo is the chief executive officer of RaQualia Pharma Inc. (4579.T).
Where is RaQualia Pharma Inc. headquartered?
RaQualia Pharma Inc. is headquartered in Japan.
Does 4579.T pay a dividend?
RaQualia Pharma Inc. (4579.T) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 4579.T go public?
RaQualia Pharma Inc. (4579.T) completed its initial public offering in 2011.